# Dare Bioscience, Inc. (DARE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/DARE
## Company Profile
- Ticker: DARE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Women's Health
## Stock Data
- Close: 0.8331 USD
- Market cap: 32056134.28 USD
- Last updated: 2026-10-06
## Business Overview
Dare Bioscience is a women’s health biotechnology company focused on contraceptive and reproductive-health innovation. Its story centers on developing products that address gaps in women’s health and family planning.
## Why The Stock Is Moving

As of Oct 6, 2026, DARE closed down 1.19% at $0.8331. No new same-company headline was identified in the current news window.

## Geographic Base

Dare is headquartered in the United States and listed on NASDAQ. It sits in specialty women’s health biotechnology.

## Business Model

The company depends on clinical progress, commercial strategy, and the ability to keep a focused women’s-health pipeline funded. Investors watch product development and market access.

## Landscape Position

Dare occupies a niche women’s-health position within biotech. It is more focused on reproductive-health innovation than on broad therapeutic diversification.

## Future Catalysts

- Daré’s catalysts are hormonal-contraception and women’s-health programs, plus any commercial step that clarifies the company’s path. The market will care about execution more than concept.

## Recent News
- 2020-02-06 13:00 EST — [Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates](https://biopharmsignal.com/news/DARE/dar-bioscience-regains-compliance-with-nasdaq-minimum-equity-rule-and-secures-ca-8353cdba) — Source: Dare Bioscience, Inc.
- 2020-02-05 13:00 EST — [Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference](https://biopharmsignal.com/news/DARE/dar-bioscience-to-present-at-the-2020-bio-ceo-investor-conference-bbc79b94) — Source: Dare Bioscience, Inc.
- 2020-01-30 13:00 EST — [Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule](https://biopharmsignal.com/news/DARE/dar-bioscience-regains-compliance-with-nasdaq-minimum-bid-price-rule-80988a97) — Source: Dare Bioscience, Inc.
- 2020-01-15 13:00 EST — [Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update](https://biopharmsignal.com/news/DARE/dar-bioscience-schedules-conference-call-for-january-22-2020-to-discuss-ovaprene-f2871c2d) — Source: Dare Bioscience, Inc.
- 2019-12-18 13:00 EST — [Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study](https://biopharmsignal.com/news/DARE/dar-bioscience-announces-fda-clearance-of-ind-application-for-dare-bv1-for-bacte-79cd26aa) — Source: Dare Bioscience, Inc.